- Pain management
Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 3.8 Bn in 2022, growing at a CAGR of 38.2% from 2023-2029. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne Awareness Day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the World's Duchenne Awareness Day. In 2015, U.S. FDA published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for drugs such as ezutromid of summit therapeutics a phase II clinical trial drug that received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.
Fastest Growing Market
Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of Market. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in the UK, while 349 new cases were reported in the U.S. in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about Duchenne muscular dystrophy is also propelling the growth of the Market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of Duchenne muscular dystrophy.
Middle East and Africa (MEA)
The duchenne muscular dystrophy treatment market was valued at USD 3.8 billion in 2022
The duchenne muscular dystrophy treatment market key players are: Bristol-Myers Squibb(U.S) FibroGen, Inc (U.S) ITALFARMACO S.p.A. (Italy) Catabasis Pharmaceuticals, Inc.(U.S) NS Pharma, Inc. (U.S) Marathon Pharmaceuticals, LLC (U.S) ReveraGen BioPharma, Inc. (U.S) Pfizer (U.S) Summit Therapeutics plc (U.K) Taiho Pharmaceutical Co (Japan) Sarepta Therapeutics, Inc. (U.S) Santhera Pharmaceuticals PTC Therapeutics (Switzerland)
The duchenne muscular dystrophy treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.